Pleura and Peritoneum...

Über diese Zeitschrift

The journal published all abstracts of the 14th International Congress of the PSOGI/ISSPP “Peritoneal Surface Malignancies – Entering the Era of Multidisciplinarity and Precision Medicine” as a separate supplement in the 2024 volume.

On that occasion, we are delighted to announce that the journal awards full waivers to the 3 best submissions from the event, as judged by a jury of members of the journal’s Editorial Board. The journal further awards 1 full waiver to the presenter of an excellent poster at the Congress. Please submit your manuscript online: https://mc.manuscriptcentral.com/pap and indicate your participation in the conference in the cover letter.

Objective
Pleura and Peritoneum is the official journal of the International Society for the Study of Pleura and Peritoneum (ISSPP).
Peritoneal and pleural infections and oncological diseases often result in life-threatening conditions. However, the pleura (serous membrane, which forms the lining of the pleural cavity) and the peritoneum (serous membrane, which forms the lining of the abdominal cavity) have been relatively poorly studied, as compared to other organs. In sharp contrast to the skin, which is recognized as an organ and object of a medical specialty, pleura and peritoneum are only considered as membranes. This might be explained by the fact that these organs cannot be seen, neither by clinical examination nor by radiological methods. Pleura and Peritoneum wants to change this by creating a high-level exchange platform for basic scientists, clinical researchers and physicians.
Pleura and Peritoneum is published quarterly. All contributions submitted for publication in Pleura and Peritoneum are subject to single-anonymized peer review by at least two experts in the field, selected and invited by the Editor-in-Chief. Pleura and Peritoneum publishes only English-language articles.
Pleura and Peritoneum is an open access journal. To sustain the publication of all fully peer-reviewed manuscripts, each article accepted for publication in Pleura and Peritoneum is subject to an article processing charge (APC), paid by authors' affiliated institutions, funders, sponsors or institutions that have an agreement with us.

Topics
Diagnosis and treatment of diseases of the human organs pleura and peritoneum // Pleural effusions // Laparoscopy // Thoracoscopy // Surgery // Gynecology // Imaging // Oncological diseases // Anatomy // Cytology // Gene therapy // Radiotherapy // Systemic drug therapy

Article formats
Research Article // Review Article // Opinion Paper// Editorial // Letter to the Editor & Reply// Short Communication // Clinical Images // Congress Abstracts

Ihre Vorteile

Innovative and groundbreaking approach to the study of the pleura and peritoneum
Interdisciplinary approach to the subject matter
Cutting-edge and authoritative contributions
Renowned international editors and editorial board
Authors retain copyright - publication under the Creative Commons Attribution (CC-BY-4.0) License
Every article easily discoverable because of SEO and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico

Open Access
Comparison of clinical characteristics and outcomes between patients with complicated pleural infection caused by Streptococcus anginosus group and Klebsiella pneumoniae

26. September 2025

Chang Ho Kim, Ji Eun Park, Sun Ha Choi, Yong Hoon Lee, Hyewon Seo, Seung Soo Yoo, Shin Yup Lee, Seung Ick Cha, Jaehee Lee

PDF downloaden

Objectives Complicated pleural infections present significant challenges. Predominant causative microorganisms include the Streptococcus anginosus group (SAG) and Klebsiella pneumoniae (KP). However, limited data are available on the risk factors and outcomes associated with SAG-related pleural infection compared to KP-related pleural infection. Methods This retrospective study was conducted in patients who underwent pleural drainage due to complicated pleural infection at Kyungpook National University Hospital in South Korea between January 2011 and December 2023. Clinical characteristics, drug resistance profiles, and outcomes were compared between patients with SAG-related and KP-related pleural infections. Results A total of 432 patients were assessed. Among them, 161 (37 %) had positive pleural fluid cultures, with SAG (n=68, 42 %) and KP (n=34, 21 %) being the predominant pathogens. Thus, 102 patients with complicated pleural infection caused by SAG or KP were analyzed. SAG cases were associated with higher rates of chronic neurologic disease, lower rates of diabetes mellitus, prolonged symptom duration, elevated white blood cell counts, and positive gram stains on pleural fluid compared to KP cases. There were no significant differences observed between the two groups regarding radiological findings. SAG strains showed resistance rates exceeding 20 % to penicillin, erythromycin, tetracycline, and clindamycin, while remaining largely susceptible to commonly used third-generation cephalosporins, ampicillin, and fluoroquinolones. The in-hospital mortality rates were approximately 10 %, consistent across both groups. Conclusions SAG-related pleural infections showed distinct clinical features, including more frequent chronic neurologic disease, but in-hospital mortality was comparable to that of KP-related infections.
Open Access
Assessing data completeness in the international society for the study of pleura and peritoneum (ISSPP) PIPAC database: a multicenter evaluation from 2020–2024

30. Juni 2025

Magnus Skov Jørgensen, Pernille Shjødt Hansen, Claus Wilki Fristrup, Martin Hübner, Jimmy So, Anne-Cecile Ezanno, Peter Hewett, Miguel Ruiz-Marin, Günther Rezniczek, Özgül Düzgün, Marc Pocard, Francesco Casella, Laura Lay, Marisa Aral, Tarkan Jäger, Felix Laminger, Oliver Glehen, Claire-Angéline Goutard, Laurent Villeneuve, Andrea Di Giorgio, Michael Bau Mortensen

PDF downloaden

Objectives In 2020, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) reached stage 2b of the IDEAL framework and a prospective international PIPAC database was launched in June 2020 by the International Society for the Study of the Pleura and Peritoneum (ISSPP). The ISSPP PIPAC database consists of six key elements, which are reported in an annual report. The ISSPP Registry Group decided to investigate data completeness within the ISSPP PIPAC Database. Methods Retrospective analysis of data completeness in the six key elements was performed between October 1st and 14th, 2024. This was complemented by an in-depth analysis of missing data in Response Evaluation, Complications, and Follow-up . Results Thirty centers, 950 patients, and 2777 PIPAC procedures were registered in the ISSPP database by October 2024. Sixteen of the 30 centers had included patients. Incomplete data were observed in four of the six key elements. Most centers (7/16) had incomplete data in Complications , followed by Response evaluation (5/16), and Follow-up (2/16). In depth analysis showed that, e.g., for complications, the date and type of the complication was registered in 88 and 89 %, respectively. Incomplete data in Response evaluation occurred mainly in the small group of patients evaluated by nonperitoneal regression grading score (non-PRGS, n=316), where no scoring was provided in 211 patients (72 %). Follow-up data, such as date of death or reasons for stopping PIPAC, were provided for 86 and 85 % of patients. Conclusions Overall data completeness of the ISSPP PIPAC Database was considered satisfactory at the present state, and the ISSPP Registry Group has launched several initiatives to further improve data completeness and quality, to provide solid data sets for future annual reports and other research.
Open Access
The addition of collagenase to BromAc^® for the management of inoperable pseudomyxoma peritonei – in vitro results

1. Januar 2000

Carissa Vici, Mathew Eapen, Pooja Narang, David L. Morris

PDF downloaden

Objectives Pseudomyxoma peritonei (PMP) is a rare peritoneal malignancy. BromAc ® is a novel therapeutic agent which has been developed to dissolve and facilitate the drainage of mucin as a palliative treatment for PMP; however, its effect is significantly reduced in patients with hard mucin. This study aimed to assess whether combining collagenase or cysteamine with BromAc ® would be more effective in dissolving hard mucin. Methods This preclinical human in vitro study examined the effect of adding collagenase to BromAc ® on hard mucin samples when incubated at 37 °C over 24 h. The effect of cysteamine alone and in combination with collagenase and BromAc ® was also examined as a supplementary arm of this study. Five experiments were conducted with appropriate controls. Human hard mucin samples were sliced into equal fractions using a sterile surgical scalpel, weighed and noted. The leftover solid mucin was weighed at 0, 1, 3, 5, and 24 h post-treatment. Results At 24 h post-treatment, all combinations with collagenase demonstrated almost 100 % dissolution of hard mucin. At 3 and 5 h post-treatment, only BromAc ® with collagenase at 250 μg/mL was found to be superior to BromAc ® alone. Combinations with cysteamine were not found to be effective. Conclusions This study provides promising evidence of the efficacy and synergistic effect of combining BromAc ® with collagenase to dissolve hard mucin. Further preclinical and clinical research should be undertaken to assess its safety and efficacy in the clinical setting.
Open Access
Co-occurrence of peritoneal mesothelioma and genitourinary cancers: a case series with comparative outcomes

1. Januar 2000

Emma M. Bradley, James L. Rogers, Marissa C. Kuo, Deepa Magge

PDF downloaden

Objectives Peritoneal mesothelioma (PM) shares features with genitourinary (GU) malignancies, including histologic appearance, embryologic origin and genetic predispositions. However, data on their co-occurrence are limited. The study presents a case series of PM patients with associated GU malignancies and explores outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Methods A prospectively maintained CRS-HIPEC database from a tertiary referral center (2011–2024) was reviewed. Demographics, tumor characteristics and outcomes were compared between PM patients with and without GU malignancies (including gynecologic and urologic cancers). Results Among 237 CRS-HIPEC patients, 8/17 patients with PM were found to have another GU malignancy (median age 52.8, 62.5 % male). This included renal cell carcinoma, prostate cancer, ovarian tumors and cervical carcinoma. Most GU malignancies were diagnosed before PM (5/8), two were diagnosed post-CRS-HIPEC, and one synchronously. Three patients reported asbestos exposure; two had BAP1 mutations. Compared to those without GU malignancies, affected patients tended to have higher PCI (19.8 vs. 14.3) and poorer 3-year survival (62.5 vs. 100 %). Conclusions GU malignancy is common among PM patients undergoing CRS-HIPEC and could represent a higher-risk subgroup. These findings raise the hypothesis of a potential association between PM and GU malignancy. Shared origins, oncogenesis of similar cell types, environmental exposures or genetic predispositions may contribute and warrant further investigation.
Open Access
Advancements in nebulizers for pressurized intraperitoneal aerosol chemotherapy (PIPAC)

1. Januar 2000

Xiaosong Lin, Zifeng Yang, Yong Li

PDF downloaden

Introduction Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative intraperitoneal drug delivery technique utilizing a nebulizer to aerosolize liquid chemotherapy agents under pressure, distributing them evenly throughout the peritoneal cavity to achieve therapeutic effects. As increasing clinical evidence supports the safety and efficacy of PIPAC as a promising treatment for peritoneal metastasis, optimizing nebulizer technology to enhance treatment outcomes has garnered significant research interest. Content Following initial investigations into the internal structure, mechanical properties, and optimization parameters of the original PIPAC nebulizer, researchers worldwide have focused on refining nebulizer design and exploring innovative applications of aerosolization devices, resulting in the development of several clinically applicable nebulizers with distinct characteristics. Summary This review aims to provide a comprehensive examination of the global advancements in PIPAC nebulizer development, the nebulizer alternative devices, evaluation parameters and methods, as well as future research directions, aiming to inform the development, optimization, and application of novel nebulizers for PIPAC, thereby contributing to the advancement of this promising therapeutic approach. Outlook Current methods for evaluating nebulizer performance are continually being refined, and the integration of nebulizers with other physical modalities holds great promise for further improving PIPAC outcomes.
Open Access
Adhesion obstacles effect on PIPAC patients with primary unresectable or recurrent platinum-resistant peritoneal metastasis from ovarian cancer

1. Januar 2000

Christos Iavazzo, Ioannis D. Gkegkes

PDF downloaden

Special Issue: PIPAC Clinical Trials (Part 1)

Special Issue: Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPEC, Guest Editor: Paul H. Sugarbaker

Journal Impact Factor	2.4	2024, Journal Citation Reports (Clarivate, 2025)
5-year Journal Impact Factor	2.1	2024, Journal Citation Reports (Clarivate, 2025)
Journal Citation Indicator	0.63	2024, Journal Citation Reports (Clarivate, 2025)
CiteScore	3.3	2024, Scopus (Elsevier B.V., 2025)
SCImago Journal Rank	0.536	2024, SJR (Scimago Lab, 2025; Data Source: Scopus)
Source Normalized Impact per Paper	0.718	2024, CWTS Journal Indicators (CWTS B.V., 2025; Data Source: Scopus)

Weitere Informationen über Zeitschriftenmetriken

You can easily submit your manuscript online. Simply go to https://mc.manuscriptcentral.com/pap and you will be guided through the entire submission and publishing process.
Prepare your manuscript according to the Instructions for Authors and Submission Checklist.
Pleura and Peritoneum follows Tier 3 of our Data Sharing Policy. Authors are required to provide a data availability statement. Please refer to the Data Sharing Policy for guidance on how to write a data availability statement.
As a condition of submission, the Template for Ethical and Legal Declarations must be customized by the submitting author on behalf of all others and uploaded as a separate Word file.
If you have any general questions please visit our FAQ page for authors.

Editor in Chief
Marc A. Reymond, University Hospital, Department of Surgery and Transplantation, Tübingen, Germany

Associate Editors
Frédéric Bibeau, University of Montpellier, Montpellier, France
Wim Ceelen, Ghent University, Ghent, Belgium
Ben Davidson, University of Oslo, Oslo, Norway
Marc Pocard, University Paris Diderot, Paris, France
Clemens B. Tempfer, Ruhr-University Bochum, Bochum, Germany

Editorial Board
Katalin Dobra, Karolinska University, Stockholm, Sweden
Ambrogio Fassina, University of Padova, Padova, Italy
Diane Goéré, Institut Gustave Roussy, Cancer Center, Villejuif, France
Sarah Herrick, The University of Manchester, Manchester, UK
Kazuho Honda, Showa University School of Medicine, Tokyo, Japan
Masato Kanzaki, Tokyo Women’s Medical University, Tokyo, Japan
Kunio Kawanishi, University of California, San Diego, CA, USA
Laura Lambert, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Ulrich Lauer, University of Tübingen, Tübingen, Germany
Maurie Markman, Cancer Treatment Centers of America, Philadelphia, PA, USA
Amit Merchea, Jacksonville, FL, USA
Claire W. Michael, Case Western Reserve University Cleveland, OH, USA
Faheez Mohamed, Hampshire Hospitals, NHS, Basingstoke, UK
Steve Mutsaers, University of Western Australia, Perth, Australia
Martin K. Oehler, Royal Adelaide Hospital, Adelaide, Australia
Kurt Van der Speeten, Ziekenhuis Oost Limburg, Genk, Belgium
Wei Peng Yong, National University Hospital Singapore, Singapore

Executive Secretary
Wiebke Solass
E-mail: wiebke.solass@t-online.de

Pleura and Peritoneum ist in den folgenden Services indiziert:

Baidu Scholar
Cabells Journalytics
Chronos Hub
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO Discovery Service
EMBASE
GoOA
Google Scholar
Indextra (Medical Library)
J-Gate
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
Publons
PubMed
PubMed Central
QOAM (Quality Open Access Market)
ReadCube
ScienceON (Korea Institute of Science and Technology Information)
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
Text Mining
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - Emerging Sources Citation Index
WorldCat (OCLC)
X-MOL
Yewno Discover

Medizin Klinische Medizin Chirurgie Chirurgie, andere

Zeitschriften Informationen

Weitere Informationen

eISSN:

2364-768X

Sprache:

Englisch

Verlag:

De Gruyter

Weitere Informationen

Erstveröffentlichung:

20. März 2016

Erscheinungsweise:

4 Hefte pro Jahr

Pleura and Peritoneum

Über diese Zeitschrift

Ihre Vorteile

Zusatzmaterial

Fachgebiete

Pleura and Peritoneum

Übersicht

Über diese Zeitschrift

Ihre Vorteile

Ahead-of-Publication / Just-Accepted

Ausgaben

Metriken

Einreichen

Editorial

Abstracting und Indexing

Zusatzmaterial

Zusatzmaterial

Fachgebiete

Fachgebiete

Externe Links

Bibliographische Daten